Comparison · NCT04375397-sae
Ibrutinib 420 mg + SOC vs Placebo + SOC: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ibrutinib 420 mg + SOC vs Placebo + SOC: serious adverse events. Trial comparisons, record NCT04375397-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04375397-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.182 | 0.0731 | 0.385 | wilson | |
| Risk in group 2 | 0.125 | 0.0434 | 0.31 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0568 | -0.158 | 0.276 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.45 | 0.366 | 5.79 | log | |
| Odds ratio, group 1 over group 2 | 1.56 | 0.307 | 7.89 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Ibrutinib 420 mg + SOC than on Placebo + SOC | 17.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ibrutinib 420 mg + SOC | 420 mg ibrutinib administered once daily as three hard gelatin capsules (140 mg each) with approximately 240 mL of water for up to 28 days and supportive care (standard-of-care, SOC) | 4 | 22 | EG000 |
| Group 2 | Placebo + SOC | Three hard gelatin placebo capsules administered once daily with approximately 240 mL of water for up to 28 days and supportive care (standard-of-care, SOC) | 3 | 24 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
All-cause mortality is reported from enrollment to the end of study; median time on follow-up was Ibrutinib 420 mg + SOC (58.0 days); and Placebo + SOC (62.0 days). Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the first dose of study drug until 30 days after last dose, up to 70 days.
Source ClinicalTrials.gov
Trial
- Title
- Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury
- NCT number
- NCT04375397
- Phases
- PHASE2
- Conditions
- CoronaVirus Induced Disease-2019 (COVID-19)
- Interventions
- Ibrutinib, Placebo
- Lead sponsor
- AbbVie
- Results first posted
- 2022-06-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04375397?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04375397-sae